Exicure, a Chicago developer of nucleic acid drugs, closed a $11.2 million funding led by Yantai-based Luye Pharma. Exicure is developing gene silencing and immunotherapeutic drugs using its proprietary three-dimensional Spherical Nucleic Acid (SNA™) constructs to deliver the drug. So far, it has completed a small Phase I trial of a topical psoriasis treatment. Exicure, which previously received backing from Bill Gates and other tech leaders, has formed a $790 million collaboration/out-licensing agreement with Purdue Pharma for its lead psoriasis drug and three other targets.
Source: China Biotoday
